Ovid Therapeutics (OVID) analyst forecast and price target
Analyst forecast
Consensus of 10 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Oct 9, 2026 |
| Guggenheim | Initiated Coverage | Buy | $7.00 | Oct 6, 2026 |
| Guggenheim | Initiated Coverage | Buy | $7.00 | Oct 5, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $5.00 from $4.00 | Sep 11, 2026 |
| Oppenheimer | Maintained | Outperform | $9.00 from $7.00 | Aug 3, 2026 |
| Wedbush | Maintained | Outperform | $7.00 | Apr 15, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $4.00 from $2.00 | Apr 9, 2026 |
| BTIG | Maintained | Buy | $4.00 | Mar 26, 2026 |
| Wedbush | Maintained | Outperform | $7.00 from $5.00 | Mar 20, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $2.00 | Dec 22, 2025 |
| LifeSci Capital | Initiated Coverage | Outperform | $4.00 | Dec 22, 2025 |
| Roth Capital | Initiated Coverage | Buy | $3.00 | Dec 11, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $2.00 from $1.50 | Nov 24, 2025 |
| Leerink Partners | Initiated Coverage | Outperform | $5.00 | Nov 17, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $1.50 from $2.00 | May 27, 2025 |
| BTIG | Maintained | Buy | $4.00 from $5.00 | Mar 24, 2025 |
| Wedbush | Maintained | Outperform | $3.00 from $4.00 | Mar 12, 2025 |
| Oppenheimer | Upgraded | Perform → Outperform | $4.00 | Jan 29, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $3.00 | Dec 4, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $3.00 | Sep 30, 2024 |
Frequently asked questions
What is the price target for OVID stock?
The average 12-month analyst price target for Ovid Therapeutics (OVID) is $7.00, with a high estimate of $9.00 and a low of $5.00, across 3 analysts.
Is OVID a buy, sell, or hold?
Analysts covering Ovid Therapeutics currently average a Buy rating: 10 buy, 0 hold and 0 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for OVID?
The average price target of $7.00 implies 219.63% upside from the last price of $2.19.
What is the latest analyst rating on OVID?
On Oct 9, 2026, Cantor Fitzgerald initiated coverage of Ovid Therapeutics at Overweight.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.